NSCLC患者外周血中KLRG1+NK细胞水平检测及其临床意义OA
Levels of KLRG1+NK cells in peripheral blood of NSCLC patients and their clinical significances
目的:探讨非小细胞肺癌(NSCLC)患者外周血中杀伤细胞凝集素样受体G1(KLRG1)+自然杀伤(NK)细胞水平,阐明其与临床指标的关联性,并评估其临床意义.方法:纳入2020-2022年在四川省肿瘤医院接受手术治疗的154例肺腺癌患者作为研究对象.采集患者临床资料[性别、年龄、体质量指数(BMI)、吸烟史、饮酒史、肿瘤家族史和pTNM分期]及术前1~2周血常规指标.采用流式细胞术检测外周血单个核细胞(PBMCs)中KLRG1+NK细胞百分率,采用x²检验或Fisher确切概率法分析KLRG1+NK 细胞百分率与临床特征的关联性,采用Mann-Whitney U检验或Kruskal-Wallis H检验比较不同组间免疫细胞亚群百分率,通过Spearman秩相关分析KLRG1+NK细胞百分率与血常规指标的相关性.结果:154例患者中,男性 51例(33.12%)、女性 103例(66.88%),年龄<55岁74例(48.05%)、≥55岁80例(51.95%).流式细胞术,外周血PBMCs中KLRG1+NK细胞百分率中位值为 17.05%(11.55%~23.98%),以该中位值为界分为NK细胞低百分率组(≤17.05%)和NK细胞高百分率组(>17.05%)后,x²检验显示患者性别与KLRG1+NK细胞百分率分组存在显著关联(x²=5.78,P=0.017),而KLRG1+NK细胞百分率与患者年龄、BMI、吸烟史、饮酒史、家族史及pTNM分期无关联(P>0.05).KLRG1+NK细胞百分率中位值为54.85%(38.20%~69.00%),与pTNM分期无关联(P>0.05).Spearman秩相关分析,KLRG1+NK细胞百分率与血小板(PLT)计数呈显著正相关关系(rho=0.18,P=0.024),与平均血小板体积(MPV)呈显著负相关关系(rho=-0.24,P=0.008).结论:NSCLC患者外周血KLRG1+NK细胞百分率随肿瘤分期进展呈降低趋势,且与PLT和MPV有关,外周血KLRG1+NK细胞百分率联合血小板参数有望作为NSCLC病情评估的潜在生物标志物.
Objective:To discuss the level of killer cell lectin-like receptor G1(KLRG1)+natural killer(NK)cells in peripheral blood of patients with non-small cell lung cancer(NSCLC),to clarify its association with the clinical indicators,and to evaluate its clinical significance.Methods:A total of 154 patients with lung adenocarcinoma who underwent surgical treatment in Sichuan Cancer Hospital from 2020 to 2022 were enrolled as the study subjects.The clinical data,such as gender,age,body mass index(BMI),smoking history,drinking history,family history of tumor,and pathological tumor-node-metastasis(pTNM)stage,and routine blood test indicators 1-2 weeks before surgery were collected.Flow cytometry was used to detect the percentage of KLRG1+NK cells in peripheral blood mononuclear cells(PBMCs);x2 test or Fisher's exact test was used to analyze the association between the percentage of KLRG1+NK cells and clinical characteristics;Mann-Whitney U test or Kruskal-Wallis H test was used to compare the percentages of immune cell subsets among different groups;Spearman rank correlation analysis was used to analyze the correlation between the percentage of KLRG1+NK cells and routine blood test indicators.Results:Among the 154 patients,there were 51 males(33.12%)and 103 females(66.88%);74 patients(48.05%)were younger than 55 years old,and 80 patients(51.95%)were 55 years old or older.The flow cytometry results showed that the median percentage of KLRG1+NK cells in peripheral blood PBMCs was 17.05%(11.55%-23.98%).Using this median as the cut-off value,the patients were divided into NK cell low percentage group(≤17.05%)and NK cell high percentage group(>17.05%).The x2 test results showed that there was a significant association between gender and the grouping of KLRG1+NK cell percentage(x2=5.78,P=0.017),while the percentage of KLRG1+NK cells was not associated with age,BMI,smoking history,drinking history,family history,or pTNM stage(P>0.05).The median percentage of KLRG1+NK cells was 54.85%(38.20%-69.00%),and it was not associated with pTNM stage(P>0.05).The Spearman rank correlation analysis results showed that the percentage of KLRG1+NK cells was significantly positively correlated with platelet(PLT)count(rho=0.18,P=0.024),and significantly negatively correlated with mean platelet volume(MPV)(rho=-0.24,P=0.008).Conclusion:The percentage of KLRG1+NK cells in peripheral blood of patients with NSCLC has decrease trendency with tumor stage progression,and is related to PLT and MPV.The percentage of peripheral blood KLRG1+NK cells combined with PLT parameters is expected to be a potential biomarker for the evaluation of NSCLC condition.
刘欣;张雨阳;曾德玲;刘晓琴;张璐;李玫颖;陈洪;曹邦荣;马士淇
四川省肿瘤医院 四川省肿瘤临床医学研究中心 电子科技大学附属肿瘤医院实验研究部,四川 成都 610041四川省肿瘤医院 四川省肿瘤临床医学研究中心 电子科技大学附属肿瘤医院实验研究部,四川 成都 610041四川省肿瘤医院 四川省肿瘤临床医学研究中心 电子科技大学附属肿瘤医院健康管理中心,四川 成都 610041四川省肿瘤医院 四川省肿瘤临床医学研究中心 电子科技大学附属肿瘤医院胸外科,四川 成都 610041四川省肿瘤医院 四川省肿瘤临床医学研究中心 电子科技大学附属肿瘤医院实验研究部,四川 成都 610041四川省肿瘤医院 四川省肿瘤临床医学研究中心 电子科技大学附属肿瘤医院实验研究部,四川 成都 610041四川省肿瘤医院 四川省肿瘤临床医学研究中心 电子科技大学附属肿瘤医院实验研究部,四川 成都 610041四川省肿瘤医院 四川省肿瘤临床医学研究中心 电子科技大学附属肿瘤医院实验研究部,四川 成都 610041||肿瘤类器官临床转化四川省工程研究中心,四川 成都 610041四川省肿瘤医院 四川省肿瘤临床医学研究中心 电子科技大学附属肿瘤医院实验研究部,四川 成都 610041
医药卫生
癌非小细胞肺杀伤细胞凝集素样受体G1自然杀伤细胞血小板免疫治疗
Cancer,non-small-cell lungKiller cell lectin-like receptor G1Natural killer cellsPlateletsImmuneotherapy
《吉林大学学报(医学版)》 2026 (3)
746-754,9
国家自然科学基金项目(82573569,82303645)四川省科技厅中央引导地方科技发展专项(2024ZYD0073)
评论